We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Reaction to Vancomycin Linked to Immune System HLA Variant

By LabMedica International staff writers
Posted on 25 Mar 2019
A simple and inexpensive assay for the HLA-A*32:01 genetic variant was developed for routine use in diagnostic laboratories to identify patients likely to suffer from vancomycin-associated drug rash with eosinophilia and systemic symptoms (DRESS).

DRESS is a severe reaction to antibiotic treatment caused by an aberrant T-cell mediated immune response that is characterized by fever, widespread skin rash, and internal organ damage. More...
Vancomycin is a prevalent cause of DRESS, which commonly occurs in the setting of combination antibiotic therapy. Variations in human leukocyte antigen (HLA) class I in particular have been associated with serious T-cell mediated adverse drug reactions, which has led to preventive screening strategies for some drugs.

Investigators at Vanderbilt University Medical Center (Nashville, TN, USA) sought to determine if variation in the HLA region was associated with vancomycin-induced DRESS and whether a diagnostic test could detect this association. For this study, the investigators analyzed data from Vanderbilt University Medical Center's biobank, BioVU, which contains approximately 250,000 unique DNA samples linked to de-identified patient records.

Results of this survey revealed that 86% of patients who developed probable vancomycin-associated DRESS carried the genetic variation HLA-A*32:01, compared to none of the matched control patients, who received vancomycin treatment and did not develop DRESS. HLA-A is one particular group within the human Class I major histocompatibility complex (MHC). It consists of several hundred different genes and several thousand variant alleles. HLA-A is critical to the cytotoxic T-cell controlled immune response to viruses and other intracellular pathogens. Because each HLA-A gene has a high affinity for slightly different peptides, certain HLA-As are associated with increased risk, more rapid progression, and/or increased severity of many diseases.

The investigators determined that approximately 20% of patients with the HLA-A*32:01 variant who began vancomycin treatment developed DRESS within four weeks. To detect such individuals the investigators developed a simple and inexpensive diagnostic test for HLA-A*32:01 that could be introduced into routine diagnostic laboratories.

“We think this test will be important in the clinical care of patients starting vancomycin and will prevent mortality and short- and long-term complications,” said senior author, Dr. Elizabeth Phillips, professor of medicine, pharmacology, pathology, microbiology, and immunology at Vanderbilt University Medical Center. “This observation also represents significant progress as we zero in on the mechanisms of these life-threatening immune-mediated drug reactions.”

The work was published in the February 15, 2019, online edition of the Journal of Allergy and Clinical Immunology.

Related Links:
Vanderbilt University Medical Center


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Serological Pipet Controller
PIPETBOY GENIUS
New
Automated PCR Setup
ESTREAM
New
Automated Microscope
dIFine
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.